{"id":"NCT02096861","sponsor":"Celltrion","briefTitle":"Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-19","primaryCompletion":"2016-01-11","completion":"2017-02-15","firstPosted":"2014-03-26","resultsPosted":"2018-04-11","lastUpdate":"2018-05-09"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P13","otherNames":[]},{"type":"BIOLOGICAL","name":"Remicade","otherNames":[]}],"arms":[{"label":"CT-P13 - CT-P13","type":"EXPERIMENTAL"},{"label":"CT-P13 - Remicade","type":"ACTIVE_COMPARATOR"},{"label":"Remicade - Remicade","type":"ACTIVE_COMPARATOR"},{"label":"Remicade - CT-P13","type":"EXPERIMENTAL"}],"summary":"This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.","primaryOutcome":{"measure":"The Number and Percentage of Patients Achieving Clinical Response According to Crohn's Disease Activity Index (CDAI)-70 Criteria at Week 6","timeFrame":"at Week 6","effectByArm":[{"arm":"CT-P13","deltaMin":77,"sd":null},{"arm":"Remicade","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["35435862","34216825","33245751","30929895","29411318"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":56},"commonTop":["Abdominal pain","Anaemia","Infusion-related reaction","Arthralgia","Influenza"]}}